Rapamycin

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle: C. Vezina, et al.; J. Antibiot. (Tokyo) 28, 721 (1975) | Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization: S.N. Sehgal, et al.; J. Antibiot. (Tokyo) 28, 727 (1975) | Inhibition of T and B lymphocyte proliferation by rapamycin: J.E. Kay, et al.; Immunology 72, 544 (1991) | FK506 and rapamycin: novel pharmacological probes of the immune response: J.Y. Chang, et al.; TIPS 12, 218 (1991) (Review) | Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases: J. Chung, et al.; Cell 69, 1227 (1992), | Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes: W.G. Morice, et al.; J. Biol. Chem. 268, 22737 (1993) | A mammalian protein targeted by G1-arresting rapamycin-receptor complex: E.J. Brown, et al.; Nature 369, 756 (1994) | Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells: S. Muthukkumar, et al.; Transplantation 60, 264 (1995) | Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro: Y. Shi, et al.; Cancer Res. 55, 1982 (1995) | Mechanism of action of the immunosuppressant rapamycin: F.J. Dumont & Q. Su; Life Sci. 58, 373 (1996) (Review) | Rapamycin causes poorly reversible inhibition of mTOR and induces p53- independent apoptosis in human rhabdomyosarcoma cells: H. Hosoi, et al.; Cancer Res. 59, 886 (1999) | Rapamycin in transplantation: a review of the evidence: R.N. Saunders, et al.; Kidney Int. 59, 3 (2001) (Review) | Rapamycin in cardiovascular medicine: P.N. Ruygrok, et al.; Intern. Med. J. 33, 103 (2003) (Review) | Rapamycin: an anti-cancer immunosuppressant?: B.K. Law; Crit. Rev. Oncol. Hematol. 56, 47 (2005) (Review) | Tubers and tumors: rapamycin therapy for benign and malignant tumors: D.R. Plas & G. Thomas; Curr. Opin. Cell Biol. 21, 230 (2009) (Review) | Potential use of rapamycin in HIV infection: M. Donia, et al.; Br. J. Clin. Pharmacol. 70, 784 (2010) (Review) | Resveratrol and rapamycin: are they anti-aging drugs? M. Kaeberlein; Bioessays 32, 96 (2010) | Fighting neurodegeneration with rapamycin: mechanistic insights: J. Bov?, et al.; Nat. Rev. Neurosci. 12, 437 (2011) (Review) | Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma: S. Greenberger, et al.; J. Invest. Dermatol. 131, 2467 (2011) | Inhibition of the PI3K?Akt and mTORC1 signaling pathways promotes the elongation of vascular endothelial cells: K. Tsuji-Tamura & M. Ogawa; J. Cell Sci. 129, 1165 (2016) | Chemically defined and growth-factor-free culture system for the expansion and derivation of human pluripotent stem cells: S. Yasuda, et al.; Nature Biomed. Eng. 2, 173 (2018) | PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation: J. Chen & Z.J. Chen, Nat. 564, 71 (2018)